Vertex Pharma (VRTX)

216.05 +0.84 (0.39%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/1/21 *Est.)

Latest Headlines

Form 8-K VERTEX PHARMACEUTICALS For: Nov 20 November 20, 2020 8:48 AM - SEC Filing Vertex (VRTX) PT Raised to $288 at UBS November 20, 2020 7:29 AM - StreetInsider Bernstein Starts Vertex (VRTX) at Outperform November 19, 2020 4:55 PM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Nov 16 Filed by: Sachdev Amit November 18, 2020 4:16 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Nov 16 Filed by: Parini Michael November 18, 2020 4:13 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Nov 16 Filed by: Arbuckle Stuart A November 18, 2020 4:11 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Nov 16 Filed by: ALTSHULER DAVID November 18, 2020 4:10 PM - SEC Filing Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation November 13, 2020 4:01 PM - BizWire Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19 November 12, 2020 4:01 PM - BizWire Form 4 VERTEX PHARMACEUTICALS For: Nov 10 Filed by: SACHS BRUCE I November 12, 2020 8:18 AM - SEC Filing Vertex (VRTX) PT Lowered to $21 at Morgan Stanley November 12, 2020 4:08 AM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Nov 04 Filed by: Parini Michael November 6, 2020 4:10 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Nov 03 Filed by: Arbuckle Stuart A November 5, 2020 4:16 PM - SEC Filing Vertex Pharma (VRTX) Reports European Commission Approval of Label Extension for KALYDECO (ivacaftor) November 5, 2020 5:58 AM - StreetInsider Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age November 5, 2020 4:00 AM - BizWire CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition November 4, 2020 9:15 AM - Globe NewsWire Form 10-Q VERTEX PHARMACEUTICALS For: Sep 30 October 30, 2020 4:14 PM - SEC Filing Vertex (VRTX) PT Lowered to $300 at Cowen October 30, 2020 7:18 AM - StreetInsider Vertex (VRTX) PT Lowered to $285 at Credit Suisse October 30, 2020 6:49 AM - StreetInsider Vertex (VRTX) PT Lowered to $247 at RBC Capital October 30, 2020 6:23 AM - StreetInsider Vertex (VRTX) PT Lowered to $307 at Barclays October 30, 2020 5:09 AM - StreetInsider Vertex (VRTX) PT Lowered to $277 at Stifel October 30, 2020 4:57 AM - StreetInsider Form 8-K VERTEX PHARMACEUTICALS For: Oct 29 October 29, 2020 4:05 PM - SEC Filing Vertex Pharma (VRTX) Tops Q3 EPS by 30c, Revenues Beat October 29, 2020 4:02 PM - StreetInsider Vertex Reports Third-Quarter 2020 Financial Results October 29, 2020 4:01 PM - BizWire UPDATE: Vertex (VRTX) Initiated at Buy at UBS October 27, 2020 4:50 PM - StreetInsider Vertex (VRTX) PT Lowered to $280 at Jefferies October 26, 2020 8:19 AM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Oct 15 Filed by: SACHS BRUCE I October 19, 2020 4:16 PM - SEC Filing Form 4 VERTEX PHARMACEUTICALS For: Oct 15 Filed by: MCKENZIE DIANA October 19, 2020 4:14 PM - SEC Filing Vertex to Announce Third-Quarter 2020 Financial Results on October 29 October 19, 2020 4:01 PM - BizWire Amicus Therapeutics (FOLD) on Watch on Chatter October 16, 2020 9:50 AM - StreetInsider Pre-Open Stock Movers 10/15: (SPI) (ORGO) (CARS) Higher; (FSLY) (VRTX) (AA) Lower (more...) October 15, 2020 9:25 AM - StreetInsider Oxurion NV Business Update – Q3 2020 October 15, 2020 2:00 AM - StreetInsider After-Hours Stock Movers 10/14: (ORGO) (ARWR) (SNBR) Higher; (FSLY) (NET) (DDOG) Lower (more...) October 14, 2020 6:09 PM - StreetInsider Arrowhead Pharma (ARWR) Gains After Vertex Pharma (VRTX) Discontinues VX-814, Shares Up 15% October 14, 2020 4:51 PM - StreetInsider Vertex Pharma (VRTX) has decided to stop dosing in trial and will discontinue development of VX-814 October 14, 2020 4:49 PM - StreetInsider Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency October 14, 2020 4:30 PM - BizWire Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer October 13, 2020 11:45 AM - StreetInsider Form 4 VERTEX PHARMACEUTICALS For: Oct 05 Filed by: Bhatia Sangeeta N. October 7, 2020 4:12 PM - SEC Filing Vertex Pharma (VRTX) Announces FDA Approves KALYDECO as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age September 25, 2020 8:03 AM - StreetInsider FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age September 25, 2020 8:00 AM - BizWire Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators September 24, 2020 5:25 AM - BizWire CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX) Announce PRIME Designation Granted by EMA to CTX001 for Treatment of Sickle Cell Disease September 22, 2020 9:01 AM - StreetInsider CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease September 22, 2020 9:00 AM - Globe NewsWire Form 8-K VERTEX PHARMACEUTICALS For: Sep 18 September 21, 2020 4:15 PM - SEC Filing Pre-Open Movers 09/17: (SRNE) (MLHR) (RIGL) Higher; (SBBP) (NCNA) (SNOW) Lower (more...) September 17, 2020 9:29 AM - StreetInsider After-Hours Movers 9/16: (MLHR) (SCS) (MRNA) Higher; (SBBP) (NCNA) (FSLR) Lower (more...) September 16, 2020 5:35 PM - StreetInsider Moderna (MRNA), Vertex (VRTX) Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing September 16, 2020 4:30 PM - StreetInsider Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing September 16, 2020 4:30 PM - BizWire Vertex Pharma (VRTX) Announces EMA Type II Variation MAA Validation for KAFTRIO in Combination with ivacaftor in People with One Copy of the F508del Mutation September 14, 2020 6:36 AM - StreetInsider  Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People w September 14, 2020 4:15 AM - BizWire Vertex Pharma (VRTX) Announces Positive Phase 3 Study for TRIKAFTA in Children Ages 6-11 Years With CF to Support Submissions for Global Regulatory Approvals September 10, 2020 9:04 AM - StreetInsider Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Ap September 10, 2020 9:00 AM - BizWire The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland September 10, 2020 3:57 AM - BizWire Vertex Pharma (VRTX) Announces FDA Accepts its sNDA for TRIKAFTA, SYMDEKO and KALYDECO for Additional CFTR Mutations September 1, 2020 9:03 AM - StreetInsider FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for September 1, 2020 9:00 AM - BizWire Form 4 VERTEX PHARMACEUTICALS For: Aug 25 Filed by: MCGLYNN MARGARET G August 26, 2020 4:15 PM - SEC Filing Full Article List